ABSTRACT
Induction of broadly neutralizing antibodies targeting ectodomain of the transmembrane (TM) glycoprotein gp41 HIV-1 provides a basis for the development of a universal anti-viral vaccine. The HeLa cell-derived TZM-bl reporter cell line is widely used for the estimation of lentiviruses neutralization by immune sera. The cell line is highly permissive to infection by most strains of HIV, SIV, and SHIV. Here we demonstrated that TZM-bl cells express a 48 kDa non-glycosylated protein (p48) recognized by broadly neutralizing monoclonal antibody (mAb) 2F5 targeting the ELDKWA (aa 669-674) epitope of gp41TM of HIV-1. A significant amount of p48 was found in the cell supernatant. The protein was identified as human kynureninase (KYNU), which has the ELDKWA epitope. The protein is further called "p48 KYNU". The HIV-1 neutralization by mAb 2F5 and 4E10 in the presence of p48KYNU was tested on Jurkat and TZM-bl cells. It was demonstrated that p48KYNU reduces neutralization by 2F5-like antibodies, but it has almost no effect on mAb 4E10. Therefore, p48KYNU can attenuate HIV-1 neutralization by 2F5-like antibodies and hence create false-negative results. Thus, previously tested immune sera that recognized the ELDKWA-epitope and demonstrated a "weak neutralization" of HIV-1 in TZM-bl assay should be reevaluated.
Subject(s)
Antibodies, Monoclonal/metabolism , Antibodies, Neutralizing/metabolism , Broadly Neutralizing Antibodies/metabolism , HIV Antibodies/metabolism , HIV Envelope Protein gp41/immunology , HIV-1/immunology , Hydrolases/metabolism , Animals , Chlorocebus aethiops , Epitopes/immunology , HEK293 Cells , HIV Envelope Protein gp41/chemistry , HeLa Cells , Hep G2 Cells , Humans , Hydrolases/chemistry , Hydrolases/genetics , Jurkat Cells , Neutralization Tests , Protein Domains , Vero CellsABSTRACT
The HIV-1 gp120/gp41 trimer undergoes a series of conformational changes in order to catalyze gp41-induced fusion of viral and cellular membranes. Here, we present the crystal structure of gp41 locked in a fusion intermediate state by an MPER-specific neutralizing antibody. The structure illustrates the conformational plasticity of the six membrane anchors arranged asymmetrically with the fusion peptides and the transmembrane regions pointing into different directions. Hinge regions located adjacent to the fusion peptide and the transmembrane region facilitate the conformational flexibility that allows high-affinity binding of broadly neutralizing anti-MPER antibodies. Molecular dynamics simulation of the MPER Ab-stabilized gp41 conformation reveals a possible transition pathway into the final post-fusion conformation with the central fusion peptides forming a hydrophobic core with flanking transmembrane regions. This suggests that MPER-specific broadly neutralizing antibodies can block final steps of refolding of the fusion peptide and the transmembrane region, which is required for completing membrane fusion.
Subject(s)
Broadly Neutralizing Antibodies/metabolism , HIV Antibodies/metabolism , HIV Envelope Protein gp41/antagonists & inhibitors , HIV-1/immunology , Single-Domain Antibodies/metabolism , Antibody Specificity , Binding Sites, Antibody , Broadly Neutralizing Antibodies/immunology , HEK293 Cells , HIV Antibodies/immunology , HIV Envelope Protein gp41/immunology , HIV Envelope Protein gp41/metabolism , Humans , Lipid Bilayers , Membrane Fusion , Molecular Dynamics Simulation , Protein Binding , Protein Conformation , Protein Folding , Protein Stability , Single-Domain Antibodies/immunology , Structure-Activity RelationshipABSTRACT
HIV-1 vaccine research has obtained an enormous boost since the discovery of many broadly neutralizing antibodies (bnAbs) targeting all accessible sites on the HIV-1 envelope glycoprotein (Env). This in turn facilitated high-resolution structures of the Env glycoprotein in complex with bnAbs. Here we focus on gp41, its highly conserved heptad repeat region 1 (HR1), the fusion peptide (FP) and the membrane-proximal external region (MPER). Notably, the broadest neutralizing antibodies target MPER. Both gp41 HR1 and MPER are only fully accessible once receptor-induced conformational changes have taken place, although some studies suggest access to MPER in the close to native Env conformation. We summarize the data on the structure and function of neutralizing antibodies targeting gp41 HR1, FP and MPER and we review their access to Env and their complex formation with gp41 HR1, MPER peptides and FP within native Env. We further discuss MPER bnAb binding to lipids and the role of somatic mutations in recognizing a bipartite epitope composed of the conserved MPER sequence and membrane components. The problematic of gp41 HR1 access and MPER bnAb auto- and polyreactivity is developed in the light of inducing such antibodies by vaccination.
Subject(s)
Antibodies, Neutralizing/chemistry , Antibodies, Neutralizing/immunology , HIV Antibodies/immunology , HIV Envelope Protein gp41/immunology , AIDS Vaccines/immunology , Animals , Epitopes/immunology , HIV Envelope Protein gp41/genetics , HIV-1/genetics , HIV-1/immunology , Humans , Mice , MutationABSTRACT
Potent and broadly neutralizing antibodies (bnAbs) are the hallmark of HIV-1 protection by vaccination. The membrane-proximal external region (MPER) of the HIV-1 gp41 fusion protein is targeted by the most broadly reactive HIV-1 neutralizing antibodies. Here, we examine the structural and molecular mechansims of neutralization by anti-MPER bnAb, LN01, which was isolated from lymph-node-derived germinal center B cells of an elite controller and exhibits broad neutralization breadth. LN01 engages both MPER and the transmembrane (TM) region, which together form a continuous helix in complex with LN01. The tilted TM orientation allows LN01 to interact simultaneously with the peptidic component of the MPER epitope and membrane via two specific lipid binding sites of the antibody paratope. Although LN01 carries a high load of somatic mutations, most key residues interacting with the MPER epitope and lipids are germline encoded, lending support for the LN01 epitope as a candidate for lineage-based vaccine development.
Subject(s)
Antibodies, Neutralizing/immunology , HIV Antibodies/immunology , HIV Envelope Protein gp41/immunology , HIV-1/immunology , AIDS Vaccines/immunology , Amino Acid Sequence/genetics , Animals , Cell Line , Disease Models, Animal , Female , HEK293 Cells , Humans , Mice , Mice, Transgenic , Protein Domains/immunologyABSTRACT
The 10E8 antibody targets a helical epitope in the membrane-proximal external region (MPER) and transmembrane domain (TMD) of the envelope glycoprotein (Env) subunit gp41 and is among the broadest known neutralizing antibodies against HIV-1. Accordingly, this antibody and its mechanism of action valuably inform the design of effective vaccines and immunotherapies. 10E8 exhibits unusual adaptations to attain specific, high-affinity binding to the MPER at the viral membrane interface. Reversing the charge of the basic paratope surface (from net positive to net negative) reportedly lowered its neutralization potency. Here, we hypothesized that by increasing the net positive charge in similar polar surface patches, the neutralization potency of the antibody may be enhanced. We found that an increased positive charge at this paratope surface strengthened an electrostatic interaction between the antibody and lipid bilayers, enabling 10E8 to interact spontaneously with membranes. Notably, the modified 10E8 antibody did not gain any apparent polyreactivity and neutralized virus with a significantly greater potency. Binding analyses indicated that the optimized 10E8 antibody bound with a higher affinity to the epitope peptide anchored in lipid bilayers and to Env spikes on virions. Overall, our data provide a proof of principle for the rational optimization of 10E8 via manipulation of its interaction with the membrane element of its epitope. However, the observation that a similar mutation strategy did not affect the potency of the first-generation anti-MPER antibody 4E10 shows possible limitations of this principle. Altogether, our results emphasize the crucial role played by the viral membrane in the antigenicity of the MPER-TMD of HIV-1.IMPORTANCE The broadly neutralizing antibody 10E8 blocks infection by nearly all HIV-1 isolates, a capacity which vaccine design seeks to reproduce. Engineered versions of this antibody also represent a promising treatment for HIV infection by passive immunization. Understanding its mechanism of action is therefore important to help in developing effective vaccines and biologics to combat HIV/AIDS. 10E8 engages its helical MPER epitope where the base of the envelope spike submerges into the viral membrane. To enable this interaction, this antibody evolved an unusual property: the ability to interact with the membrane surface. Here, we provide evidence that 10E8 can be made more effective by enhancing its interactions with membranes. Our findings strengthen the idea that to elicit antibodies similar to 10E8, vaccines must reproduce the membrane environment where these antibodies perform their function.
Subject(s)
Antibodies, Neutralizing/immunology , Cell Membrane/immunology , HIV Antibodies/immunology , HIV Envelope Protein gp41/antagonists & inhibitors , HIV Infections/immunology , HIV-1/immunology , Antibodies, Neutralizing/pharmacology , Cell Line , HIV Antibodies/pharmacology , HIV Envelope Protein gp41/immunology , HIV Infections/drug therapy , HIV Infections/pathology , HumansABSTRACT
The exceptional breadth of broadly neutralizing antibodies (bNAbs) against the membrane-proximal external region (MPER) of the transmembrane protein gp41 makes this class of antibodies an ideal model to design HIV vaccines. From a practical point of view, however, the preparation of vaccines eliciting bNAbs is still a major roadblock that limits their clinical application. Fresh mechanistic insights are necessary to develop more effective strategies. In particular, the function of the unusually long complementarity-determining region three of the heavy chain (CDRH3) of 4E10, an anti-MPER bNAb, is an open question that fascinates researchers in the field. Residues comprising the apex region are dispensable for engagement of the epitope in solution; still, their single mutation profoundly impairs the neutralization capabilities of the antibody. Since this region is very hydrophobic, it has been proposed that the apex is essential for anchoring the antibody to the viral membrane where MPER resides. Herein, we have critically examined this idea using structural, biophysical, biochemical, and cell-based approaches. Our results demonstrate that the apex region is not just a "greasy" spot merely increasing the affinity of the antibody for the membrane. We demonstrate the three-dimensional engagement of the apex region of the CDRH3 with the conglomerate of gp41 epitope and membrane lipids as a means of effective binding and neutralization of the virus. This mechanism of recognition suggests a standard route of antibody ontogeny. Therefore, we need to focus our efforts on recreating a more realistic MPER/lipid immunogen in order to generate more effective anti-HIV-1 vaccines.
Subject(s)
Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/metabolism , HIV Antibodies/chemistry , HIV Antibodies/metabolism , HIV Envelope Protein gp41/metabolism , HIV-1/immunology , Antibodies, Monoclonal/genetics , Broadly Neutralizing Antibodies , Cell Membrane/metabolism , Crystallography, X-Ray , Epitopes/chemistry , Epitopes/metabolism , HEK293 Cells , HIV Antibodies/genetics , HIV Envelope Protein gp41/chemistry , Humans , Lipid Bilayers , TryptophanABSTRACT
The 4E10 antibody displays an extreme breadth of HIV-1 neutralization and therefore constitutes a suitable model system for structure-guided vaccine design and immunotherapeutics against AIDS. In this regard, the relevance of autoreactivity with membrane lipids for the biological function of this antibody is still a subject of controversy. To address this dispute, herein we have compared the membrane partitioning ability of the 4E10 antibody and several of its variants, which were mutated at the region of the paratope surface in contact with the membrane interface. We first employed a physical separation approach (vesicle flotation) and subsequently carried out quantitative fluorescence measurements in an intact system (spectroscopic titration), using 4E10 Fab labeled with a polarity-sensitive fluorescent probe. Moreover, recognition of epitope peptide in membrane was demonstrated by photo-cross-linking assays using a Fab that incorporated the genetically encoded unnatural amino acid p-benzoylphenylalanine. The experimental data ruled out that the proposed stereospecific recognition of viral lipids was necessary for the function of the antibody. In contrast, our data suggest that nonspecific electrostatic interactions between basic residues of 4E10 and acidic phospholipids in the membranes contribute to the observed biological function. Moreover, the energetics of membrane partitioning indicated that 4E10 behaves as a peripheral membrane protein, tightening the binding to the ligand epitope inserted in the viral membrane. The implications of these findings for the natural production and biological function of this antibody are discussed.
Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Neutralizing/immunology , Cell Membrane/immunology , HIV Antibodies/immunology , AIDS Vaccines , Antibodies, Monoclonal/adverse effects , Antibodies, Neutralizing/adverse effects , Autoimmunity , Broadly Neutralizing Antibodies , Cell Line , Drug Design , Epitopes , HIV Antibodies/adverse effects , Humans , Membrane Lipids/immunology , Viral Matrix Proteins/immunologyABSTRACT
Peptide vaccines have been shown effective in preventing animal infection in some instances, and various formulations are under evaluation for their potential clinical use in humans. In the case of the Human Immunodeficiency Virus type-1 (HIV-1) infection, viral escape from immune surveillance restricts relevant neutralizing humoral responses to a handful of sites of vulnerability on the envelope glycoprotein. The membrane-proximal external region (MPER) on the gp41 transmembrane subunit has been identified as the only linear B-epitope that embodies an HIV vulnerability site. Thus, focusing humoral responses to MPER by peptide-based immunogens is a pursued goal in HIV vaccine development. The location of this sequence in the vicinity of the membrane interface, its composition (rich in aromatic residues), and the requirement of long-hydrophobic heavy-chain third complementarity-determining region loops for antibody-mediated neutralization suggests that in addition to the specific amino acid composition, antigenicity and immunogenicity of MPER can be modulated by membrane lipids. In this chapter, we give an overview of applications of lipid vesicles (liposomes) to the development of MPER-targeting vaccines, both as type-B adjuvants and epitope structure-shaping devices.
Subject(s)
AIDS Vaccines/immunology , Epitopes/immunology , HIV Envelope Protein gp41/immunology , HIV/immunology , Peptides/immunology , AIDS Vaccines/chemistry , Animals , Epitopes/chemistry , Humans , Liposomes/chemistry , Liposomes/immunology , Peptides/chemistry , Protein ConformationABSTRACT
The replicative cycle of the human immunodeficiency virus type-1 begins after fusion of the viral and target-cell membranes. The envelope glycoprotein gp41 transmembrane subunit contains conserved hydrophobic domains that engage and perturb the merging lipid bilayers. In this work, we have characterized the fusion-committed state generated in vesicles by CpreTM, a synthetic peptide derived from the sequence connecting the membrane-proximal external region (MPER) and the transmembrane domain (TMD) of gp41. Pre-loading cholesterol-rich vesicles with CpreTM rendered them competent for subsequent lipid-mixing with fluorescently-labeled target vesicles. Highlighting the physiological relevance of the lasting fusion-competent state, the broadly neutralizing antibody 4E10 bound to the CpreTM-primed vesicles and inhibited lipid-mixing. Heterotypic fusion assays disclosed dependence on the lipid composition of the vesicles that acted either as virus or cell membrane surrogates. Lipid-mixing exhibited above all a critical dependence on the cholesterol content in those experiments. We infer that the fusion-competent state described herein resembles bona-fide perturbations generated by the pre-hairpin MPER-TMD connection within the viral membrane.
Subject(s)
Cell Membrane/chemistry , Cholesterol/chemistry , HIV Envelope Protein gp41/chemistry , HIV-1/chemistry , Membrane Fusion/physiology , Membrane Lipids/chemistry , Peptide Fragments/chemistry , Cell Membrane/metabolism , Cholesterol/metabolism , HIV Envelope Protein gp41/metabolism , HIV-1/metabolism , Humans , Membrane Lipids/metabolism , Peptide Fragments/metabolism , SphingomyelinsABSTRACT
Objective To study the amino acid mutations in neutralizing antibody 2F5 and 4E10 conserved epitopes ELDKWA and NWFDIT of HIV-1 membrane proximal external region(MPER)in 92 HIV-infected individuals and AIDS patients in China,and to provide a basis for the neutralizing antobodies immunotherapy and a design of vaccines. Methods Nest-PCR methods were used to amplity genes of the HIV-1 env gp41 region.The amplified fragments were sequenced by double-deoxygen terminal method and translated into amino acids for analysis.The mutations of 2F5 and 4E10 neutralizing epitopes were identified by comparison with the epitopes reference data in HIV-1 Sequence Database.Results There were mutations on both 2F5 and 4E10 neutralizing epitopes.2F5 conserved neutralizing epitopes major mutations tocused on E662A(14.1%),K665S(17.4%),A667K(16.3%),and 4E10 conserved neutralizing epltopes major mutations included N671S(13.0%),D674S(3.3%),T676S(16.3%).The mutation rates of 2F5 and 4E10 epitopes were significanfly different between CRF_B'C-clade and B'-clade(P<0.05).The mutata rates of CRF_B'C-clade were higher than that of CRFOI_AE-clade in 2F5 epitopes(P<0.05).The mutation rates of B'-clade in 4E10 eiptopes showed significant difference in slow progressors,HIV-infected individuals and AIDS patients,respectively(P<0.05).Conclusion The HIV-1 patients in China are demonstrated diversified mutations in 2F5 and 4E10 neutralizing epitopes.The mutation degrees of amlno acids in conserved neutralizing epitopes are different in different subtypes.There may be a correlation between neutralizing epitopes mutations of 4E10 with disease progression.